Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?
Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.
Why Wenda Pharma’s Phase II data puts BET inhibition back in focus for NUT carcinoma
NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.
Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy
Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.
What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
Can darlifarnib overcome VEGF resistance in kidney cancer? Explore what Kura Oncology’s latest data could mean for future treatment strategies.
What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Why the TACTI-004 Phase III outcome challenges assumptions about LAG-3 immune activation
Immutep Limited halts its TACTI-004 lung cancer trial after a futility analysis. Discover what the setback means for eftilagimod alfa and LAG-3 immunotherapy.
How Citius Oncology’s LYMPHIR program reflects a broader shift in immuno-oncology strategy
Citius Oncology reports early LYMPHIR plus pembrolizumab data in gynecologic cancers. Explore what the study reveals about the future of immuno-oncology strategies.
How Incyte’s retifanlimab approval could reshape first-line therapy for advanced anal cancer in Europe
European regulators approve retifanlimab for advanced anal cancer. Discover what this means for immunotherapy treatment strategies in rare oncology today.